SWITCHING FROM ONABOTULINUMTOXIN-A TO ABOBOTULINUMTOXIN-A IN CHILDREN WITH CEREBRAL PALSY TREATED FOR SPASTICITY: A RETROSPECTIVE SAFETY AND EFFICACY EVALUATION

被引:6
作者
Dursun, Nigar [1 ]
Akarsu, Melike [1 ]
Gokbel, Tugba [1 ]
Akyuz, Merve [1 ]
Karacan, Cagla [1 ]
Dursun, Erbil [1 ]
机构
[1] Kocaeli Univ, Med Fac Umuttepe, Dept Phys Med & Rehabil, Fac Med, TR-41380 Kocaeli, Izmit, Turkey
关键词
botulinum toxin; cerebral palsy; spasticity; abobotulinumtoxin-A; onabotulinumtoxin-A; Dysport; Botox; BOTULINUM-TOXIN-A; ADOLESCENTS;
D O I
10.2340/16501977-2550
中图分类号
R49 [康复医学];
学科分类号
100215 ;
摘要
Objectives: To determine whether switching from onabotulinumtoxin-A to abobotulinumtoxin-A in children with cerebral palsy is safe and whether therapeutic efficacy is maintained. Methods: This retrospective observational study of routine care included 118 children with cerebral palsy (mean age 81.4 months (standard deviation 38.9)) who had switched from onabotulinumtoxinA to abobotulinumtoxin-A injections into their lower extremities due to a change in hospital policy. Analysis was limited to the final onabotulinumtoxin-A treatment-cycle prior to switch, and the first abobotulinumtoxin- A treatment-cycle following switch. The primary objective was to document the safety and tolerability of switching products. Efficacy endpoints included muscle tone, spasticity, and gait function based on Modified Ashworth Scale (MAS), Tardieu Scale (TS) and Observational Gait Scale (OGS) scores. Results: Treatment-emergent adverse events were recorded in 41 (34.7%) and 31 (26.3%) patients during the onabotulinumtoxin-A and abobotulinumtoxin- A treatment cycles, respectively. Treatment-related adverse events were reported in 5 patients in the onabotulinumtoxin-A treatment-cycle vs 7 in the abobotulinumtoxin-A treatment-cycle (p = 0.774). Treatment efficacy (4-6 weeks post-treatment) was similar in the onabotulinumtoxin-A and abobotulinumtoxin- A treatment-cycles for all variables (MAS, TS, OGS). Conclusion: In children with cerebral palsy, switching from onabotulinumtoxin-A to abobotulinumtoxin- A is safe and generally well-tolerated and therapeutic efficacy is maintained.
引用
收藏
页码:390 / 394
页数:5
相关论文
共 14 条
[1]   Safety of botulinum toxin type A among children with spasticity secondary to cerebral palsy: a systematic review of randomized clinical trials [J].
Albavera-Hernandez, Cidronio ;
Rodriguez, Jorge M. ;
Idrovo, Alvaro J. .
CLINICAL REHABILITATION, 2009, 23 (05) :394-407
[2]  
[Anonymous], 2012, SPAST CHILDR YOUNG P
[3]   Practice Parameter: Pharmacologic treatment of spasticity in children and adolescents with cerebral palsy (an evidence-based review) Report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society [J].
Delgado, M. R. ;
Hirtz, D. ;
Aisen, M. ;
Ashwal, S. ;
Fehlings, D. L. ;
McLaughlin, J. ;
Morrison, L. A. ;
Shrader, M. W. ;
Tilton, A. ;
Vargus-Adams, J. .
NEUROLOGY, 2010, 74 (04) :336-343
[4]   Safety and Efficacy of Repeat Open-Label AbobotulinumtoxinA Treatment in Pediatric Cerebral Palsy [J].
Delgado, Mauricio R. ;
Bonikowski, Marcin ;
Carranza, Jorge ;
Dabrowski, Edward ;
Matthews, Dennis ;
Russman, Barry ;
Tilton, Ann ;
Carlos Velez, Juan ;
Grandoulier, Anne-Sophie ;
Picaut, Philippe .
JOURNAL OF CHILD NEUROLOGY, 2017, 32 (13) :1058-1064
[5]   The updated European Consensus 2009 on the use of Botulinum toxin for children with cerebral palsy [J].
Heinen, Florian ;
Desloovere, Kaat ;
Schroeder, A. Sebastian ;
Berweck, Steffen ;
Borggraefe, Ingo ;
van Campenhout, Anya ;
Andersen, Guro L. ;
Aydin, Resa ;
Becher, Jules G. ;
Bernert, Guenther ;
Martinez Caballero, Ignacio ;
Carr, Lucinda ;
Valayer, Emmanuelle Chaleat ;
Desiato, Maria Teresa ;
Fairhurst, Charlie ;
Filipetti, Paul ;
Hassink, Ralph-Ingo ;
Hustedt, Ulf ;
Jozwiak, Marek ;
Kocer, Serdar Ibrahim ;
Kolanowski, Elisabeth ;
Kraegeloh-Mann, Ingeborg ;
Kutlay, Sehim ;
Maenpaa, Helena ;
Mall, Volker ;
McArthur, Paul ;
Morel, Edith ;
Papavassiliou, Antigone ;
Pascual-Pascual, Ignacio ;
Pedersen, Soren Anker ;
Plasschaert, Frank S. ;
van der Ploeg, Irene ;
Remy-Neris, Olivier ;
Renders, Anne ;
Di Rosa, Guiseppe ;
Steinlin, Maja ;
Tedroff, Kristina ;
Vidal Valls, Joan ;
Viehweger, Elke ;
Molenaers, Guy .
EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY, 2010, 14 (01) :45-66
[6]   Botulinum toxin assessment, intervention and after-care for lower limb spasticity in children with cerebral palsy: international consensus statement [J].
Love, S. C. ;
Novak, I. ;
Kentish, M. ;
Desloovere, K. ;
Heinen, F. ;
Molenaers, G. ;
O'Flaherty, S. ;
Graham, H. K. .
EUROPEAN JOURNAL OF NEUROLOGY, 2010, 17 :9-37
[7]   The effects of quantitative gait assessment and botulinum toxin A on musculoskeletal surgery in children with cerebral palsy [J].
Molenaers, G ;
Desloovere, K ;
Fabry, G ;
De Cock, P .
JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME, 2006, 88A (01) :161-170
[8]   Systemic adverse events following botulinum toxin A therapy in children with cerebral palsy [J].
Naidu, Krishant ;
Smith, Katherine ;
Sheedy, Mary ;
Adair, Brooke ;
Yu, Xavier ;
Graham, H. Kerr .
DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY, 2010, 52 (02) :139-144
[9]   Safety and efficacy of botulinum toxin type A following long-term use [J].
Naumann, M. ;
Albanese, A. ;
Heinen, F. ;
Molenaers, G. ;
Relja, M. .
EUROPEAN JOURNAL OF NEUROLOGY, 2006, 13 :35-40
[10]   Safety of Botulinum Toxin A in Children and Adolescents with Cerebral Palsy in a Pragmatic Setting [J].
Papavasiliou, Antigone S. ;
Nikaina, Irene ;
Foska, Katerina ;
Bouros, Panagiotis ;
Mitsou, George ;
Filiopoulos, Constantine .
TOXINS, 2013, 5 (03) :524-536